A small molecule inhibitor of human ARV1 sterol-binding protein blocks lipid binding
Journal of Biological Chemistry · 2026-11 · 113718
DOI: 10.1016/j.jbc.2026.113718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-11. Verfasst von Hsing-Yin Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, NJ 08691. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
ARV1 (are2 required for viability 1) sterol-binding protein is conserved across eukaryotic species and binds cholesterol, phospholipids, and phosphoinositides. Mutations in hARV1 are linked to epileptic encephalitis. mArv1-deficient mice show resistance to diet-induced obesity. Scarv1Δ cells have defects in glycosylphosphatidylinositol biosynthesis, sterol distribution and sphingolipid biosynthesis. ARV1 knockdown in human cells leads to endoplasmic reticulum cholesterol accumulation. How ARV1 regulates lipid movement is not understood. The development of inhibitors targeting the ability of ARV1 to bind lipid will provide valuable insights into its function. Employing a homogenous time-resolved fluorescence high throughput screening assay, we identified VB-84133 as an inhibitor of human ARV1 lipid binding with an IC50 of 3.2 + 0.21 μM. VB-84133 blocks the interaction of the ARV1 homology domain (AHD) with cholesterol, phosphatidylserine and other phospholipids in liposome binding assays. This inhibition was specific to ARV1 interaction, since VB-84133 did not block binding of phosphatidylserine to Annexin A2 or A5. We demonstrated that ARV1 moves phosphatidylserine between inner and outer membranes using an in vitro fluorescence-based liposome quenching assay, and that movement was inhibited by VB-84133. In phenotypic studies, S. cerevisiae ARV1 cells undergo arv1-associated cell death in the presence of VB-84133. VB-84133 constitutively activates the unfolded protein response (UPR) and XBP1 splicing in HepG2 cells but does not synergize with loss of ARV1 gene expression in further progressing splicing. VB-84133 also inhibits NBD-cholesterol localization to lipid droplets. Overall, VB-84133 specifically targets ARV1, evidenced by its capacity to bind ARV1 and trigger loss-of-function events associated with ARV1 deficiency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, NJ 08691.
- Venenum Biodesign, L.L.C., Genesis Biotechnology Group, Hamilton, NJ 08690.
- The Institute of Metabolic Disorders, Genesis Biotechnology Group, Hamilton, NJ 08691; Rutgers Center for Lipid Research, New Jersey Institute for Food, Nutrition, and Health, Rutgers University, New Brunswick, New Jers…
Zitieren
APA
Liu, H. Y., Savoly, D., Stroke, I., Francisco, J., Corbalan, J. J., Jagadeesan, P., Huang, C. Y., Beasley, J. R., & Nickels, J. T. (2026). A small molecule inhibitor of human ARV1 sterol-binding protein blocks lipid binding. Journal of Biological Chemistry, 113718. https://doi.org/10.1016/j.jbc.2026.113718
Vancouver
Liu HY, Savoly D, Stroke I, Francisco J, Corbalan JJ, Jagadeesan P, et al. A small molecule inhibitor of human ARV1 sterol-binding protein blocks lipid binding. Journal of Biological Chemistry. 2026:113718. doi:10.1016/j.jbc.2026.113718
BibTeX
@article{Liu2026,
author = {Liu, Hsing-Yin and Savoly, Diana and Stroke, Ilana and Francisco, Jamie and Corbalan, J Jose and Jagadeesan, Pranavi and Huang, Chia-Yu and Beasley, James R and Nickels, Joseph T},
title = {A small molecule inhibitor of human ARV1 sterol-binding protein blocks lipid binding},
journal = {Journal of Biological Chemistry},
year = {2026},
pages = {113718},
doi = {10.1016/j.jbc.2026.113718}
}
EUVIMED